Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO
Regeneron Pharmaceuticals, Inc. today announced positive topline results for EYLEA® (aflibercept) Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO).